The "Severe Toxicities in Lymphoma - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This 'Severe Toxicities in Lymphoma - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Severe Toxicities in Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Severe Toxicities in Lymphoma epidemiology division provides the insights about historical and current Severe Toxicities in Lymphoma patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Severe Toxicities in Lymphoma epidemiology [segmented as Total incident cases of lymphoma, Type-specific incident cases of lymphoma, Stage-specific incident cases of lymphoma, Chemotherapy treated lymphoma patients, and Frequency of Severe Toxicities in Lymphoma Patients] scenario of Severe toxicities in lymphoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.
Country Wise- Severe Toxicities in Lymphoma Epidemiology
For 2020, 198,600 incident cases of Lymphoma were estimated in the 7MM. The United States, in 2020, accounted for nearly 41% of the total 7MM cases.
Among the EU-5 countries, the highest number of cases of Lymphoma accessed for Germany, i.e. 20,855 cases in 2020, which are estimated to rise by the year 2030.
Furthermore, Japan accounted for about 17% of the total 7MM incident cases of Lymphoma in 2020.
In the 7MM, among the stage-specific Lymphoma patients, a high number of patients were estimated to be in early-stage, i.e., Stage I (73,482). This was followed by Stage IV (65,538). Contrary to this, Stage III (31,776) and Stage II (27,804) accounted for comparatively less percentage in 2020.
In the 7MM, 160,370 naive lymphoma patients, and 63,506 relapsed/refractory lymphoma patients were estimated to be treated with chemotherapy in 2020.
In the 7MM, 16,037 naive patients were estimated to suffer from severe toxicities. For the Relapsed/Refractory pool, the cases were estimated to be around 36,199 in 2020.
In 2020, 2,804 naive patients, and 6,329 relapsed/refractory cases were estimated with severe toxicities in Japan.
Key Topics Covered:
1. Key Insights
2. Executive Summary of Severe Toxicities in Lymphoma
3. Epidemiology Methodology
4. Severe Toxicities in Lymphoma: Disease Background and Overview
4.2. Staging of Lymphoma
4.3. Current therapeutic options for lymphoma
4.3.2. Targeted Therapies
4.3.3. Radiation Therapy
4.4. Severe Toxicities due to Lymphoma treatment
4.4.1. Cardiovascular Diseases
4.4.2. Pulmonary Diseases
4.4.3. Hormone problems
4.4.4. Second cancer
4.4.5. CAR T-cell toxicities
4.4.6. Other late effects
4.5. Risk factors for toxicities in lymphoma
4.6.1. Tests for Lung disorders due to toxicities
4.6.2. Tests for thyroid abnormalities due to toxicities
4.6.3. Tests for fertility in females
4.6.4. Tests for Cardiovascular disorders due to toxicities
4.6.5. Tests for Second Cancers due to toxicities
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. 7MM Epidemiology
5.3.1. Total Incident Cases of lymphoma in the 7MM
5.3.2. Type-specific Incident cases of Lymphoma in 7MM
5.3.3. Stage-Specific Incidence of Lymphoma in the 7MM
5.3.4. Chemotherapy Treated Lymphoma Patients in the 7MM
5.3.5. Frequency of Severe Toxicities in Lymphoma Patients in the 7MM
5.4. The United States Epidemiology
5.5. EU-5 Epidemiology
5.10. The United Kingdom
5.11. Japan Epidemiology
6.2. Report Methodology
7. Publisher Capabilities
For more information about this report visit https://www.researchandmarkets.com/r/dq09bb
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005557/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900